Non-Invasive Prenatal Testing / Screening
Helping Pharma companies develop Precision medicine using Clinical Data & AI.
What is the Febrile Neutropenia Panel?
Febrile Neutropenia is a critical, potentially life-threatening condition where a patient with a weakened immune system—often due to cancer chemotherapy—develops a fever indicating an underlying infection. GeneHealth’s Febrile Neutropenia Panel is a highly advanced, rapid molecular test designed to quickly and accurately identify the specific bacteria, viruses, or fungi causing the infection. This empowers oncologists and physicians to administer targeted, life-saving antimicrobial therapy without delay.
Book a Test Now →How Does It Differ From Routine Blood Tests?
| Feature | Routine Blood Culture | GeneHealth Febrile Neutropenia Panel |
|---|---|---|
| Turnaround Time | Takes 48 to 72 hours (or longer for fungi) to grow and identify the pathogen. | Rapid Turnaround. Delivers comprehensive results typically within 24 hours. |
| Pathogen Detection | Primarily detects culturable bacteria and a limited scope of yeast/fungi. Misses unculturable pathogens. | Broad Spectrum. Simultaneously detects a vast array of bacteria, viruses, and hard-to-culture fungi via nucleic acid amplification. |
| Antimicrobial Resistance | Requires additional days after the initial culture grows to test for antibiotic susceptibility. | Direct Genetic Markers. Rapidly identifies key genetic markers for antimicrobial resistance (AMR), guiding immediate drug choice. |
| Target Group | General population presenting with symptoms of systemic infection. | High-Risk Patients. Specifically designed for immunocompromised individuals, cancer patients, and transplant recipients. |
Who Should Consider This Test?
- Oncology patients currently undergoing chemotherapy who develop a fever (temp > 38.3°C / 101°F).
- Patients diagnosed with severe neutropenia (Absolute Neutrophil Count < 500 cells/mm³).
- Individuals who have recently undergone stem cell or bone marrow transplants.
- Immunocompromised patients exhibiting signs of sepsis or systemic infection.
- Patients not responding to initial, broad-spectrum empirical antibiotic treatments.
Panel Specifications
Why Choose GeneHealth for Testing?
In neutropenic patients, infections can escalate rapidly. Our molecular test delivers actionable insights days faster than traditional cultures.
Leaves no stone unturned by screening for dozens of common, rare, and opportunistic bacterial, viral, and fungal pathogens in a single run.
By identifying specific antimicrobial resistance (AMR) genes, we help physicians avoid ineffective drugs and reduce antibiotic toxicity.
